The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment

Completed

Conditions studied: Wilson Disease

In brief

This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications. After providing informed consent, participants meeting all inclusion and no exclusion criteria were enrolled into the study as outpatients. The participants' routine clinic visits were scheduled according to the standard clinical practice at the study center and at the discretion of the treating physician at approximate 6-month intervals. At the time of enrollment, participants were receiving SoC medications for the treatment of WD, which could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc. If treatment was interrupted or stopped during the course of the study, participants continued in the study and biological samples and clinical data were continued to be collected for the full 24-month study period. Dosing with SoC agents was individualized and managed by the treating physician at the study center according to standard clinical practice at the site.

Key facts

Study ID

NCT02763215

Run by

Alexion Pharmaceuticals, Inc.

People needed

64

Starts

2016-05-19

Expected to finish

2019-01-21

Last updated by the study team

2020-12-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to give informed consent for participation in the study.
• Male or female participants, aged 18 years or older as of signing the informed consent form.
• Receiving SoC medications (penicillamine, trientine, zinc, or copper chelators with zinc) for the treatment of WD at the time of enrollment and for no more than 60 months prior to enrollment.
• Able to understand and willing to comply with study procedures and requirements, as judged by the Investigator.
• Established diagnosis of WD.
• Adequate venous access to allow for collection of blood samples.

You may not qualify if…

• Major systemic disease or other illness that would, in the opinion of the Investigator, compromise participant safety or interfere with the collection or interpretation of study results.
• In the opinion of the Investigator, the participant was likely to be non-compliant or uncooperative during the study.

Where it is running

• Clinical Trial Site — New Haven, Connecticut, United States
• Clinical Trial Site — Chicago, Illinois, United States
• Clinical Trial Site — Ann Arbor, Michigan, United States
• Clinical Trial Site — Nashville, Tennessee, United States
• Clinical Trial Site — Seattle, Washington, United States
• Clinical Trial Site — Vienna, Austria
• Clinical Trial Site — Heidelberg, Germany
• Clinical Trial Site — Warsaw, Poland
• Clinical Trial Site — Birmingham, United Kingdom
• Clinical Trial Site — Guildford, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.